Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19168622 | 1.00 | MAPT (0.39) | MAPTLMNACYP19A1BAZ2BTRPV1 | |
| SCHEMBL19161127 | 1.00 | MAPT (0.39) | MAPTLMNACYP19A1BAZ2BTRPV1 | |
| SCHEMBL19167692 | 0.83 | MAPT (0.41) | MAPTLMNABAZ2BTDP1KMT2A | |
| SCHEMBL12660672 | 0.80 | KDM4E (0.46) | MAPTLMNACYP19A1BAZ2BDRD5 | |
| SCHEMBL19161104 | 0.78 | CYP19A1 (0.46) | MAPTCYP19A1TRPV1ALDH1A1 | |
| SCHEMBL19168923 | 0.78 | CYP19A1 (0.46) | MAPTCYP19A1TRPV1ALDH1A1 | |
| SCHEMBL17500265 | 0.78 | CYP19A1 (0.46) | MAPTCYP19A1TRPV1ALDH1A1 | |
| SCHEMBL19169004 | 0.77 | BAZ2B (0.52) | MAPTLMNACYP19A1BAZ2BTRPV1 | |
| SCHEMBL19167946 | 0.75 | GPX4 (0.42) | MAPTLMNABAZ2BTRPV1KMT2A | |
| SCHEMBL8250018 | 0.73 | FABP5 (0.39) | CYP19A1TRPV1FAAHKMT2AGPX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-10106540-B2 | HDAC6 inhibitors and their uses | UNIVERSITÄT REGENSBURG (DE) | 2018-10-23 | — | — | US | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3177621-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universität Regensburg (DE) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020369-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | HDAC6, HDAC5, HDAC4 | MAPT 1414/4885LMNA 2596/4885CYP19A1 4582/4885 |
| US-10106540-B2 | HDAC6 inhibitors and their uses | HDAC6, HDAC5, HDAC4 | MAPT 1324/4885LMNA 2094/4885CYP19A1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.